The Centers for Medicare & Medicaid Services yesterday approved Louisiana’s Medicaid plan amendment allowing supplemental rebate agreement negotiations with prescription drug makers for Hepatitis C therapies. The new “modified subscription” model allows the state to cap gross expenditures for the Hepatitis C prescriptions for Medicaid and requires manufacturers to provide the drug’s lowest price negotiated in all states in the Medicaid program. “The high cost of prescription drugs is one of the greatest challenges in our health care system,” said CMS Administrator Seema Verma, “and Louisiana’s innovative approach to leveraging a subscription model to promote access to hepatitis C therapy is a great example of how states can lead in designing solutions.” The amendment goes into effect July 1. CMS has approved similar state plan amendments for Washington, Oklahoma, Michigan and Colorado. This is the second one to focus on Hepatitis C.

Related News Articles

Headline
State Medicaid programs are reporting an uptick in enrollment compared with their fiscal year 2020 projections, due in part to the COVID-19 pandemic. The…
Headline
The Centers for Medicare & Medicaid Services yesterday approved a state of Washington-developed emergency demonstration project to adjust its Medicaid…
Headline
The Oklahoma Health Care Authority this week asked the Centers for Medicare & Medicaid Services to approve a Healthy Adult Opportunity…
Headline
The Centers for Medicare & Medicaid Services Friday granted a Section 1135 Medicaid waiver for the COVID-19 emergency to Utah, bringing the national…
Headline
The Medicaid and CHIP Payment and Access Commission published a pair of reports last week. In its March report to Congress, MACPAC, a key congressional advisor…
Headline
The Centers for Medicare & Medicaid Services says it has granted Section 1135 Medicaid waivers to an additional seven states. Nationwide, 23 states have…